Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Rating of “Buy” from Analysts

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) has been assigned a consensus recommendation of “Buy” from the eight analysts that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, five have given a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $31.80.

A number of equities analysts have commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research note on Tuesday, April 21st. Citigroup raised their price objective on Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the stock a “buy” rating in a research note on Monday, March 9th. Royal Bank Of Canada lowered their price objective on Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating on the stock in a research note on Thursday. Chardan Capital raised their price objective on Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Finally, HC Wainwright raised their price objective on Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th.

Insider Buying and Selling

In other Eyepoint Pharmaceuticals news, insider Ramiro Ribeiro sold 2,437 shares of the firm’s stock in a transaction on Friday, April 17th. The stock was sold at an average price of $15.00, for a total transaction of $36,555.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 4.46% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Eyepoint Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the business. KBC Group NV bought a new position in shares of Eyepoint Pharmaceuticals in the 1st quarter valued at $29,000. Swiss National Bank bought a new position in shares of Eyepoint Pharmaceuticals in the 1st quarter valued at $1,900,000. Hsbc Holdings PLC bought a new position in shares of Eyepoint Pharmaceuticals in the 1st quarter valued at $10,743,000. Janney Montgomery Scott LLC increased its stake in shares of Eyepoint Pharmaceuticals by 14.8% in the 1st quarter. Janney Montgomery Scott LLC now owns 30,315 shares of the company’s stock valued at $391,000 after purchasing an additional 3,900 shares during the last quarter. Finally, Pictet Asset Management Holding SA bought a new position in shares of Eyepoint Pharmaceuticals in the 1st quarter valued at $141,000. Institutional investors own 99.41% of the company’s stock.

Trending Headlines about Eyepoint Pharmaceuticals

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright kept a Buy rating and $30 price target on Eyepoint Pharmaceuticals while lifting several earnings estimates, including FY2026 and Q3/Q4 2026, suggesting improved expectations for the company’s outlook.
• Positive Sentiment: The firm also reiterated favorable longer-term projections for FY2027 and quarterly 2027 earnings, reinforcing the view that analysts see a path to better profitability over time.
• Neutral Sentiment: HC Wainwright’s Q2 2026 estimate was only slightly adjusted, indicating no major change in near-term expectations.
• Negative Sentiment: Royal Bank of Canada cut its price target on EYPT from $39 to $37, which may have pressured sentiment despite maintaining an Outperform rating.

Eyepoint Pharmaceuticals Trading Up 1.9%

Shares of NASDAQ EYPT opened at $13.66 on Friday. The firm has a market cap of $1.14 billion, a P/E ratio of -3.90 and a beta of 1.76. Eyepoint Pharmaceuticals has a 1-year low of $5.30 and a 1-year high of $19.11. The business’s 50 day moving average is $14.33 and its 200-day moving average is $14.62.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its earnings results on Wednesday, May 6th. The company reported ($0.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.20). The firm had revenue of $0.70 million for the quarter, compared to the consensus estimate of $0.35 million. Eyepoint Pharmaceuticals had a negative return on equity of 108.31% and a negative net margin of 3,566.63%. Analysts forecast that Eyepoint Pharmaceuticals will post -3.15 EPS for the current year.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.